相似文献
1
Strategic approaches to developing drug treatments for ALS.
Drug Discov Today. 2008 Jan;13(1-2):67-72. doi: 10.1016/j.drudis.2007.10.011. Epub 2007 Nov 26.
2
Insulin-like growth factor-I for the treatment of amyotrophic lateral sclerosis.
Amyotroph Lateral Scler. 2009 Apr;10(2):63-73. doi: 10.1080/17482960802160370.
3
[Amyotrophic lateral sclerosis. Current clinical trials and underlying pathomechanisms].
Nervenarzt. 2008 Jun;79(6):653-61. doi: 10.1007/s00115-007-2403-0.
4
Recombinant human insulin-like growth factor I (rhIGF-I) for amyotrophic lateral sclerosis/motor neuron disease.
Cochrane Database Syst Rev. 2002(3):CD002064. doi: 10.1002/14651858.CD002064.
5
Experimental trials in amyotrophic lateral sclerosis: a review of recently completed, ongoing and planned trials using existing and novel drugs.
Expert Opin Investig Drugs. 2014 Nov;23(11):1541-51. doi: 10.1517/13543784.2014.933807. Epub 2014 Jun 26.
6
[Research in amyotrophic lateral sclerosis: what is new in 2009?].
Rev Neurol (Paris). 2010 Aug-Sep;166(8-9):683-98. doi: 10.1016/j.neurol.2010.03.006. Epub 2010 May 15.
7
Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs.
Med Res Rev. 2019 Mar;39(2):733-748. doi: 10.1002/med.21528. Epub 2018 Aug 12.
8
Recombinant human insulin-like growth factor I (rhIGF-I) for amyotrophic lateral sclerosis/motor neuron disease.
Cochrane Database Syst Rev. 2007 Oct 17(4):CD002064. doi: 10.1002/14651858.CD002064.pub2.
9
Neuroprotective agents target molecular mechanisms of disease in ALS.
Drug Discov Today. 2015 Jan;20(1):65-75. doi: 10.1016/j.drudis.2014.08.016. Epub 2014 Sep 6.
10
[Current Status of Drug Development for Amyotrophic Lateral Sclerosis].
Brain Nerve. 2024 Nov;76(11):1241-1249. doi: 10.11477/mf.1416202766.
引用本文的文献
1
RNAi-mediated silencing of SOD1 profoundly extends survival and functional outcomes in ALS mice.
bioRxiv. 2024 Jun 25:2024.06.20.599943. doi: 10.1101/2024.06.20.599943.
2
Neuronal Circuit Dysfunction in Amyotrophic Lateral Sclerosis.
Cells. 2024 May 7;13(10):792. doi: 10.3390/cells13100792.
3
Copper-ATSM as a Treatment for ALS: Support from Mutant SOD1 Models and Beyond.
Life (Basel). 2020 Nov 4;10(11):271. doi: 10.3390/life10110271.
4
ALS blood expression profiling identifies new biomarkers, patient subgroups, and evidence for neutrophilia and hypoxia.
J Transl Med. 2019 May 22;17(1):170. doi: 10.1186/s12967-019-1909-0.
5
Potential new complication in drug therapy development for amyotrophic lateral sclerosis.
Expert Rev Neurother. 2016 Dec;16(12):1397-1405. doi: 10.1080/14737175.2016.1207530. Epub 2016 Jul 15.
6
Emerging from the bottleneck: benefits of the comparative approach to modern neuroscience.
Trends Neurosci. 2015 May;38(5):273-8. doi: 10.1016/j.tins.2015.02.008. Epub 2015 Mar 21.
7
Systemic pharmacokinetics and cerebrospinal fluid uptake of intravenous ceftriaxone in patients with amyotrophic lateral sclerosis.
J Clin Pharmacol. 2014 Oct;54(10):1180-7. doi: 10.1002/jcph.317. Epub 2014 May 16.
8
Clinically applicable antianginal agents suppress osteoblastic transformation of myogenic cells and heterotopic ossifications in mice.
J Bone Miner Metab. 2013 Jan;31(1):26-33. doi: 10.1007/s00774-012-0380-2. Epub 2012 Aug 24.
9
Control of neuroinflammation as a therapeutic strategy for amyotrophic lateral sclerosis and other neurodegenerative disorders.
Exp Neurol. 2010 Mar;222(1):1-5. doi: 10.1016/j.expneurol.2009.12.018. Epub 2010 Jan 4.
10
Mouse models of Huntington disease: variations on a theme.
Dis Model Mech. 2009 Mar-Apr;2(3-4):123-9. doi: 10.1242/dmm.002451.
本文引用的文献
1
Current clinical trials in amyotrophic lateral sclerosis.
Expert Opin Investig Drugs. 2007 Aug;16(8):1197-207. doi: 10.1517/13543784.16.8.1197.
2
Overexpression of mutant superoxide dismutase 1 causes a motor axonopathy in the zebrafish.
Hum Mol Genet. 2007 Oct 1;16(19):2359-65. doi: 10.1093/hmg/ddm193. Epub 2007 Jul 17.
3
Molecular and cellular function of ALS2/alsin: implication of membrane dynamics in neuronal development and degeneration.
Neurochem Int. 2007 Jul-Sep;51(2-4):74-84. doi: 10.1016/j.neuint.2007.04.010. Epub 2007 May 4.
4
Quantitative objective markers for upper and lower motor neuron dysfunction in ALS.
Neurology. 2007 Apr 24;68(17):1402-10. doi: 10.1212/01.wnl.0000260065.57832.87.
5
Recombinant human erythropoietin suppresses symptom onset and progression of G93A-SOD1 mouse model of ALS by preventing motor neuron death and inflammation.
Eur J Neurosci. 2007 Apr;25(7):1923-30. doi: 10.1111/j.1460-9568.2007.05471.x.
6
Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons.
Nat Neurosci. 2007 May;10(5):615-22. doi: 10.1038/nn1876. Epub 2007 Apr 15.
7
Non-cell autonomous effect of glia on motor neurons in an embryonic stem cell-based ALS model.
Nat Neurosci. 2007 May;10(5):608-14. doi: 10.1038/nn1885. Epub 2007 Apr 15.
8
Ethnic variation in the incidence of ALS: a systematic review.
Neurology. 2007 Mar 27;68(13):1002-7. doi: 10.1212/01.wnl.0000258551.96893.6f.
9
Lost in translation: treatment trials in the SOD1 mouse and in human ALS.
Neurobiol Dis. 2007 Apr;26(1):1-13. doi: 10.1016/j.nbd.2006.12.015. Epub 2007 Jan 3.
10
Molecular Diagnosis and Biomarker Identification on SELDI proteomics data by ADTBoost method.
Conf Proc IEEE Eng Med Biol Soc. 2005;2005:4771-4. doi: 10.1109/IEMBS.2005.1615538.
Zotero 插件